Abstract
The SARS-CoV-2 virus has emerged and rapidly evolved into a current global pandemic. Although bacterial and fungal coinfections have been associated with COVID-19, little is known about parasitic infection. We report a case of a COVID-19 patient who developed disseminated strongyloidiasis following treatment with high-dose corticosteroids and tocilizumab. Screening for Strongyloides infection should be pursued in individuals with COVID-19 who originate from endemic regions before initiating immunosuppressive therapy.
MeSH terms
-
Adrenal Cortex Hormones / administration & dosage
-
Aged
-
Animals
-
Anthelmintics / therapeutic use
-
Antibodies, Monoclonal, Humanized / administration & dosage
-
Betacoronavirus / pathogenicity
-
COVID-19
-
Coinfection
-
Connecticut
-
Coronavirus Infections / drug therapy
-
Coronavirus Infections / immunology
-
Coronavirus Infections / parasitology*
-
Coronavirus Infections / virology
-
Diabetes Mellitus / drug therapy
-
Diabetes Mellitus / immunology
-
Diabetes Mellitus / parasitology*
-
Diabetes Mellitus / virology
-
Ecuador
-
Humans
-
Hypertension / drug therapy
-
Hypertension / immunology
-
Hypertension / parasitology*
-
Hypertension / virology
-
Immunologic Factors / administration & dosage
-
Male
-
Pandemics
-
Peripheral Nervous System Diseases / drug therapy
-
Peripheral Nervous System Diseases / immunology
-
Peripheral Nervous System Diseases / parasitology*
-
Peripheral Nervous System Diseases / virology
-
Pneumonia, Viral / drug therapy
-
Pneumonia, Viral / immunology
-
Pneumonia, Viral / parasitology*
-
Pneumonia, Viral / virology
-
SARS-CoV-2
-
Strongyloides stercoralis / pathogenicity*
-
Strongyloidiasis / drug therapy
-
Strongyloidiasis / immunology
-
Strongyloidiasis / parasitology*
-
Strongyloidiasis / virology
Substances
-
Adrenal Cortex Hormones
-
Anthelmintics
-
Antibodies, Monoclonal, Humanized
-
Immunologic Factors
-
tocilizumab